Çelik Serhat, Kaynar Leylagül
Department of Hematology, Yenimahalle Training and Research Hospital, Yıldırım Beyazıt University, Ankara, Turkey.
Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Methods Mol Biol. 2025;2907:71-83. doi: 10.1007/978-1-0716-4430-0_3.
Graft-versus-host disease (GVHD) is one of the most important obstacles after allogeneic hematopoietic stem cell transplantation (allo-HCT). The mortality rate is around 50%, especially in severe GVHD. One of the most important clinical outcomes in GVHD is non-relapse mortality (NRM). NRM was defined as death without evidence of relapse or progression. Kaplan Meier, log-rank test, and Cox model are used in survival analysis methods. There are various biomarkers that assess clinical outcomes of GVHD. Damage-associated molecular patterns, pathogen-associated molecular patterns, microRNAs, markers of endothelial dysfunction, cytokines, and their receptors are used to predict the occurrence of GVHD and clinical outcomes in GVHD. Furthermore, the utilization of panels that assess many biomarkers has proven to be successful in predicting the clinical outcomes of GVHD, particularly NRM.
移植物抗宿主病（GVHD）是异基因造血干细胞移植（allo-HCT）后最重要的障碍之一。死亡率约为50%，尤其是在严重GVHD中。GVHD最重要的临床结局之一是非复发死亡率（NRM）。NRM被定义为无复发或进展证据的死亡。生存分析方法采用Kaplan Meier法、对数秩检验和Cox模型。有多种生物标志物可评估GVHD的临床结局。损伤相关分子模式、病原体相关分子模式、微小RNA、内皮功能障碍标志物、细胞因子及其受体可用于预测GVHD的发生及GVHD的临床结局。此外，评估多种生物标志物的检测板已被证明在预测GVHD的临床结局，尤其是NRM方面是成功的。
